You have access
Effect of Co-administration of Ketoconazole, a Strong CYP3A Inhibitor, on the Pharmacokinetics, Safety and Tolerability of Navitoclax, a First-in-class Oral Bcl-2 Family Inhibitor, in Cancer Patients
AHMED HAMED SALEM, JIANNING YANG, ALISON GRAHAM, AMITA PATNAIK, KYLE HOLEN, RAJENDRA PRADHAN and HAO XIONG
Anticancer Research April 2014, 34 (4) 2001-2006;